Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · IEX Real-Time Price · USD
1.340
-0.020 (-1.47%)
At close: Jul 19, 2024, 4:00 PM
1.350
+0.010 (0.75%)
Pre-market: Jul 22, 2024, 7:23 AM EDT
Company Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States.
The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020.
Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Atossa Therapeutics, Inc.
| Country | United States |
| Founded | 2009 |
| IPO Date | Nov 8, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Dr. Steven C. Quay FCAP, M.D., Ph.D. |
Contact Details
Address: 107 Spring Street Seattle, Washington 98104 United States | |
| Phone | 206.588.0256 |
| Website | atossatherapeutics.com |
Stock Details
| Ticker Symbol | ATOS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001488039 |
| CUSIP Number | 04962H506 |
| ISIN Number | US04962H5063 |
| Employer ID | 26-4753208 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, Chief Executive Officer and President |
| Heather Rees CPA | Senior Vice President of Finance and Principal Accounting Officer |
| Delly Behen P.H.R. | Senior Vice President of Administration and Human Resources |
| Eric Van Zanten | Vice President of Investor and Public Relations |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2024 | 8-K | Current Report |
| May 23, 2024 | EFFECT | Notice of Effectiveness |
| May 23, 2024 | DEF 14A | Other definitive proxy statements |
| May 21, 2024 | UPLOAD | Filing |
| May 14, 2024 | DEL AM | Filing |
| May 13, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 13, 2024 | 10-Q | Quarterly Report |
| May 13, 2024 | 8-K | Current Report |
| May 10, 2024 | ARS | Filing |
| May 10, 2024 | PRE 14A | Other preliminary proxy statements |